01 — Evidence
Evidence Summary
CBG's evidence base looks different depending on where you look: entirely absent for tumor outcomes in humans, but wide-ranging and mechanistically detailed in animal and cell models, now spanning two independent in-vivo tumor systems. Reading across all three tiers together gives the fairest picture.
Human
Clinical Record
Safety and behavioural data only
No controlled human trial has tested CBG against a tumor outcome of any kind. What exists instead: a placebo-controlled trial found a single dose measurably eased anxiety and stress in healthy adults, and a separate ascending-dose safety study found CBG well tolerated across the range tested.
A self-report survey of regular users found CBG used mainly for anxiety, pain, and sleep, with most rating it more effective than conventional options — but this is unverified, self-selected patient-reported data, not a controlled trial.
Animal
Preclinical Signal
Two independent in-vivo models
Animal evidence now spans two independent tumor systems — colorectal and prostate — plus a separate, non-tumor colitis model relevant to host resilience rather than tumor suppression directly.
- Reduced tumor growth and burden in colorectal xenograft and carcinogenesis models
- The colorectal effect required one specific receptor (TRPM8)
- A weaker, secondary tumor-suppressing effect in a prostate cancer model
- Reduced colitis severity in a separate, non-tumor inflammatory model
In Vitro
Cell Model Data
Wide-ranging; two mechanistic axes
The deepest and widest mechanistic detail of any evidence tier — spanning direct apoptosis induction, growth-receptor blockade, and a distinct route through immune-system restoration, across colorectal, glioblastoma, pancreatic, skin, and blood cancer models.
- Apoptosis induction confirmed independently in two colorectal cell panels
- EGFR-axis signalling disrupted in two cancer types, via different downstream mechanisms
- Tumor visibility to immune cells restored in metastatic tumor models
- A modest, usually secondary anti-invasive effect in two further cancer types
Human
Clinical Record
Human research on CBG hasn't yet asked the tumour question at all — every controlled study to date has looked at something else entirely. The clearest positive result is behavioural, not oncological: a double-blind, placebo-controlled crossover trial found that a single oral dose measurably reduced self-reported anxiety and stress in healthy adults, relative to placebo, with no evidence of intoxication, sedation, or motor and cognitive impairment.[5] A separate single-ascending-dose safety study, climbing from a low dose up through a much higher one, found CBG well tolerated throughout, without producing much of a measurable drug effect at any level tested.[7]
Continue reading — full research detail+
A self-report survey of regular CBG-predominant cannabis users adds a further, weaker layer of human data: respondents reported using it mainly for anxiety, chronic pain, depression, and insomnia, and a majority rated it more effective than conventional medications for those indications. The same survey captured commonly reported mild side effects — dry mouth, sleepiness, dry eyes — and some reported withdrawal-type symptoms on stopping regular use. This is unverified, self-selected patient-reported data, not a controlled trial, and should be read with that caveat throughout — respondents were using CBG-predominant cannabis preparations, which contain THC, CBD, terpenes, and other constituents alongside CBG, not isolated CBG the way the controlled trials above tested it.[8]
Signal maturity: human research currently answers questions about acute safety, tolerability, and subjective mood effects — not about whether CBG affects cancer itself. No human study of any kind has tested CBG against a tumour outcome, and no repeated-dosing human data exist for any endpoint.
Animal
Preclinical Signal
Colorectal cancer delivered CBG's clearest in-vivo result. In both a tumour-transplant model and a separate, chemically induced model of colon tumour formation, CBG reduced tumour growth and overall tumour burden — and this effect had a precise mechanistic requirement: it depended on one specific receptor (TRPM8), since the effect shrank when that receptor was silenced and was reproduced by other, unrelated drugs that block the same receptor. That's a real mechanistic confirmation, not just a correlation.[1]
Continue reading — full research detail+
A second, independent in-vivo model adds a further — weaker — tumour-suppression signal. In a mouse model of hormone-refractory prostate cancer, CBG on its own slowed disease development through changes in the tumour's metabolic and growth signalling, though this effect was clearly less pronounced than a comparator compound tested in the same study. Combined with that comparator, the effect held up even in tumours that had already stopped responding to a standard anti-androgen drug — a real signal, but a secondary one within its own source study, not CBG's own headline result.[17]
Separately, and outside the tumour-suppression story entirely, a mouse model of chemically induced colitis found that CBG reduced inflammatory markers and calmed an overactive immune-signalling molecule (nitric oxide) in macrophages, acting through a specific cannabinoid receptor (CB2). This isn't a tumour model — it speaks to how CBG affects the body's own tissue resilience, not how it affects a tumour directly, and is covered in full under Pathway Interaction Profile's Protect section below.[10]
Signal maturity: animal evidence for CBG now spans two independent tumour-suppression models — colorectal and prostate — which is a genuinely different evidentiary position than a single-model finding, though the two are not equally strong: the colorectal work is CBG-centred and mechanistically developed, while the prostate signal is secondary within a study centred on a different cannabinoid. Translation from mouse to human remains unproven either way, and neither animal finding here has been tested in a human oncology trial.
In Vitro
Cell Model Data
Two independent research groups, working with two entirely different colorectal cancer cell panels, reached the same conclusion by different routes: CBG reduces cell viability and triggers apoptosis in a dose-dependent way. In one panel, CBG's apoptotic effect ran through the same TRPM8-dependent mechanism confirmed in vivo above, paired with rising internal oxidative stress and a marker of cellular stress response (CHOP). In the second, independent panel, CBG additionally stalled the cell cycle before cells died — a proliferation-limiting effect layered on top of, not separate from, the death signal itself.[1,2]
Continue reading — full research detail+
In glioblastoma cells, CBG reduced the viability of both ordinary tumour cells and the harder-to-treat, stem-like tumour cell population, and triggered a caspase-driven cell-death programme in both — and separately, CBG reduced how far these cells could invade surrounding tissue, to roughly the same degree as a standard chemotherapy comparator.[3]
A separate mechanistic thread runs through growth-factor receptor signalling rather than direct cell death. In skin cancer cells that overexpress a specific growth receptor (EGFR), CBG was predicted by structural modelling and experimentally supported to interact with the EGFR kinase domain, reducing cell viability and triggering apoptosis.[15] In pancreatic cancer cells, a separate study reported CBG reducing both EGFR and its downstream signalling partner (RAS) — but here, the cells didn't die by the usual apoptosis route; they died by a distinct process (autophagic cell death). Together the two studies support a shared EGFR-axis theme, though they don't confirm the identical mechanism — the skin-cancer work centres on active-site kinase inhibition, the pancreatic work on downstream signalling and a different cell-death pathway.[16]
A newer and mechanistically distinct finding moves beyond direct cell killing altogether: CBG was shown to restore a marker (MHC-I) that many metastatic tumours shed specifically to hide from the immune system, increasing their capacity for recognition by cytotoxic T-lymphocytes in cell-based assays. The epigenetic signature behind this change closely resembled the one produced by interferon-gamma, the body's own signal for switching this same marker back on — a mechanistic parallel, not a claim that CBG and interferon-gamma work identically. The concentration needed for this effect varied markedly by cell model — in one murine cell line, it occurred at a concentration well below the micromolar range used throughout most of the other in-vitro work described above, while other cell lines required substantially more.[14]
In multiple myeloma cells, CBG — tested alongside three related minor cannabinoids — reduced cell growth and reduced how readily myeloma cells invaded toward bone-forming cells. CBG wasn't the strongest performer in that comparison; two of the other three compounds tested showed larger effects, and only one of them was carried forward into an animal model. CBG's own contribution here is real but secondary.[18]
Signal maturity: cell-model research offers the deepest and widest mechanistic detail of any evidence tier for CBG, identifying at least two mechanistically distinct routes to tumour cell death (apoptosis and autophagy) plus a third, non-lethal immune-restoration mechanism — but most direct cytotoxicity studies used low-to-mid micromolar concentrations, and distance from the human clinical setting is greatest here; mechanism alone does not confirm real-world benefit.
Advertisement
02 — Pathways
Pathway Interaction Profile
CBG engages several distinct biological pathways relevant to tumor behavior, grouped below by the functional role each one supports. This includes direct anti-tumour mechanisms and, further down, a separate set of pathways supporting the body's own resilience.
CBG's Contain classification rests on reported reduction of tumour cell invasiveness, now documented independently in two different cancer types — glioblastoma and multiple myeloma — even though CBG was rarely the standout performer in either study. A modest, secondary anti-invasive signal confirmed twice independently is still a real one.
Prevent Tumour Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
EMT & metastatic invasion
In glioblastoma, CBG has been reported to inhibit tumour cell invasion to a similar degree as a standard chemotherapy comparator. In multiple myeloma, CBG — tested alongside three related minor cannabinoids — reduced invasion of myeloma cells toward bone-forming cells, though it was not the strongest performer among the compounds tested. Two independent cancer types showing the same direction of effect is what supports this classification, not the size of either individual result.[3,18]
CBG's Weaken classification reflects reported interference with two of the signalling routes tumour cells depend on to keep dividing — the cell-cycle machinery directly, and the growth-factor receptor signalling that feeds it, now confirmed through two independent mechanistic angles on the same receptor.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
Cell cycle checkpoints (CDK4/6–RB–E2F, G1/S, G2/M)
In colorectal cancer cells, CBG has been reported to stall the cell cycle at the G1 checkpoint, ahead of and alongside the apoptotic outcome documented under Attack below.[2]
EGFR / HER-family signalling
In EGFR-overexpressing skin cancer cells, CBG was predicted by structural modelling and experimentally supported to interact with the EGFR kinase domain, reducing cell viability and inducing apoptosis.[15]
RAS–RAF–MEK–ERK (MAPK)
In pancreatic ductal adenocarcinoma cells, CBG has been reported to reduce EGFR and downstream RAS signalling — but here, cell death proceeded through a distinct, non-apoptotic mechanism (autophagic cell death) rather than the caspase-driven route documented elsewhere on this page.[16]
CBG's Attack classification is the best-corroborated part of its profile, anchored in apoptosis induction confirmed across independent colorectal and glioblastoma cell studies, with the colorectal signal additionally confirmed in living-animal models. A separate prostate-cancer study reported an additional, weaker tumour-suppression signal for CBG, particularly in combination with another cannabinoid, though that study did not independently establish the same apoptotic mechanism. Attack is now also joined by a mechanistically distinct route: restoring a tumour's visibility to the immune system rather than killing it directly. CBG's broader receptor pharmacology — including TRPM8, EGFR, and cannabinoid receptor engagement — underlies these routes; CBG interacts with multiple cannabinoid and non-cannabinoid targets rather than acting through one dominant receptor, which is part of why its reported mechanisms vary across the different cancer models described here.[9] The concentration gap covered under Pharmacokinetics and Administration below still applies, and no human oncology trial has tested any of these mechanisms directly.
Direct Tumour-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
This is the primary mechanistic basis for CBG's Attack classification, confirmed across colorectal cancer (in two independent cell panels and, in vivo, a xenograft and a chemically induced tumour model) and glioblastoma cell models — in colorectal cancer specifically, this route was reported to require a functional TRPM8 receptor, confirmed by silencing the receptor and by reproducing the effect with unrelated TRPM8-blocking drugs.[1,2,3]
Immune-Mediated Killing (Re-enabled)
Research concerning immune surveillance and cytotoxic execution capacity.
MHC-I / antigen-presentation restoration
CBG has been reported to reverse a tumour immune-escape strategy in vitro by restoring MHC-I surface expression on metastatic tumour cells, increasing their capacity for recognition by cytotoxic T-lymphocytes in cell-based assays — a mechanistically distinct route to Attack, separate from direct apoptosis induction, and epigenetically similar to how interferon-gamma achieves the same effect. This demonstrates antigen-presentation restoration and T-cell recognition-related activity in cell models, not tumour elimination in a living organism.[14]
CBG's Protect classification currently rests entirely on reported support for the body's own tissue resilience, independent of any drug interaction — two separate systems, each carrying real, cited support, set out below.
GI Integrity & Microbiome
Research concerning gut-barrier integrity, microbiome composition, and host immune regulation.
CB2-mediated colitis reduction
In a mouse model of chemically induced colitis, isolated CBG has been reported to reduce colon inflammation, immune-cell infiltration, and tissue injury, acting through a specific cannabinoid receptor (CB2), and separately to reduce oxidative stress within the intestinal lining itself.[10] A later study using a high-CBG hemp extract — not isolated CBG, and therefore not directly attributable to CBG alone — reported a similar direction of effect on colitis severity in a different model, alongside changes to the gut microbiome; that microbiome finding has not been established for isolated CBG specifically.[11] These findings are not necessarily contradictory with CBG's tumour-directed oxidative-stress effects described under Attack above: cannabinoid effects on oxidative and nitrosative signalling can vary by cell type, dose, and disease context. However, selective protection of normal tissue alongside tumour-cell killing by the same mechanism has not been demonstrated directly in a single comparative model.
Neuroendocrine / Sleep / Stress Axis
Human and preclinical research on neuroendocrine, sleep, and stress-axis regulation in the host.
Acute stress and anxiety reduction
In a placebo-controlled human trial, a single oral dose of CBG reduced self-reported anxiety and stress in healthy adults, without producing intoxication or measurable impairment — a direct human finding, though based on subjective self-report rather than a measured biological stress marker.[5]
Prevent Tumor Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
CBG has been reported to reduce tumor cell invasion in glioblastoma and multiple myeloma models — a modest, usually secondary effect, but confirmed independently across two different cancer types.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
CBG has been reported to block this growth-receptor pathway directly in two independent cancer cell types — skin and pancreatic — reducing viability through two mechanistically distinct routes to cell death.
Direct Tumor-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
Supported in colorectal cancer by both cell and animal models — this route required a specific receptor (TRPM8). Additional animal tumor-suppression activity has been reported in prostate cancer, though that study did not establish the same apoptotic mechanism. No human oncology trial has tested this mechanism.
Immune-Mediated Killing (Re-enabled)
Research concerning immune surveillance and cytotoxic execution capacity.
MHC-I / antigen-presentation restoration
CBG has been reported to restore a marker that lets the immune system recognize tumor cells again, in cell models across a range of metastatic tumor types — a distinct mechanism from direct cell killing.
GI Integrity & Microbiome
Research concerning gut-barrier integrity, microbiome composition, and host immune regulation.
CB2-mediated colitis reduction
CBG has been reported to reduce gut inflammation and oxidative stress in an animal model of colitis, through a specific cannabinoid receptor (CB2) — a host-protective effect working in a different tissue context from CBG's tumor-directed activity.
Advertisement
03 — Pharmacokinetics
Pharmacokinetics and Administration
How CBG moves through the body — and how much of it actually reaches the bloodstream — has more bearing on real-world use than the mechanistic evidence alone. This is the practical layer that shapes formulation, timing, and co-medication decisions, and for CBG it is also where the evidence is thinnest.
Absorption
CBG is highly lipophilic, and oral systemic exposure appears limited and variable based on animal data, though absolute oral bioavailability has not been established in humans. A high-fat meal raises peak plasma concentration relative to a low-fat meal at the same dose. Formulation-dependent absorption is a real and possibly large effect.
The Concentration Gap
Effects reported in cell studies require low-to-mid micromolar concentrations in most direct cytotoxicity work. A controlled human study measured plasma concentrations of roughly 0.003–0.028 µM after a single 25 mg oral dose — hundreds to thousands of times below the concentrations shown to have effects in cell studies.
Clinical Dose Context
Every controlled human study to date has used a single, acute dose — no repeated-dosing human data exist for CBG at any endpoint. Tested doses range from 20 mg up to 200 mg.
Formulation Effects
Formulation effects on CBG absorption are real but inconsistent across studies. A rat study found a nanoemulsion formulation dramatically outperformed a standard oil solution. A horse study found no difference between oil and micellar formulations. And in the one human study to test this directly, a plain isolate actually outperformed an emulsion, under high-fat meal conditions specifically — the opposite of what emulsification would typically be expected to do.
Metabolism
Metabolized primarily by CYP2J2, with extensive first-pass hepatic clearance. Excreted mainly as glucuronide-conjugated metabolites.
Co-Dosing Considerations
No CBG-specific clinical drug-interaction study has been published. CBG undergoes hepatic metabolism, but being metabolized by an enzyme doesn't by itself mean a compound meaningfully inhibits or induces it — interaction risk with other drugs remains uncertain rather than demonstrated.
Absorption
CBG is highly lipophilic and is administered orally almost exclusively in oil-based tinctures or capsules. In mice, CBG showed slower absorption after oral dosing than after intraperitoneal injection (blood levels peaked at roughly 180 minutes orally versus 30 minutes by injection), with oral exposure well below intraperitoneal exposure at the same dose.[4] A cross-species data point from horses put a number on oral exposure directly: roughly 28% of an oral dose reached the bloodstream — incomplete-to-moderate rather than vanishingly low — with no significant difference between an oil and a micellar formulation at that dose and species.[13] Oral systemic exposure therefore appears limited and variable across the species studied, but absolute oral bioavailability has not been established in humans — no human study has included a comparative intravenous arm, which is what that calculation requires.
What a dose is taken with matters, at least in one confirmed human comparison: a 25 mg oral dose reached a higher peak plasma concentration when taken with a high-fat meal than with a low-fat meal.[6] Whether that food effect is large or small in absolute terms wasn't established in the sources reviewed.
The Concentration Gap
Human plasma concentrations after a single 25 mg oral dose have been measured directly in a controlled pharmacokinetic study: mean Cmax ranged from 0.91 ng/mL (low-fat meal, isolate) up to 8.76 ng/mL (high-fat meal, isolate), depending on meal fat content and delivery vehicle.[6] Converted using CBG's molecular weight (≈316.5 g/mol), that range corresponds to roughly 0.003–0.028 µM — compared against the 23.5–34.9 µM colorectal IC50 range reported in vitro, human plasma exposure at this dose sits roughly 850 to over 12,000 times lower, depending on which meal/dose condition and which end of the IC50 range are compared. Plasma Cmax is not the same as intracellular or tumour-tissue concentration, so this comparison should be read as indicative rather than a precise measure of exposure at the site of action — but it is a substantial, quantifiable gap by any reading.
| Benchmark | Concentration | Context |
|---|---|---|
| Apoptosis / cell-cycle arrest IC50 (colorectal) | 23.5–34.9 µM | Two independent colorectal cancer cell lines, same source study[2] |
| EGFR-kinase inhibition (skin cancer) | Low micromolar range | Exact IC50 not reported in the source reviewed[15] |
| Achievable human oral plasma exposure | 0.91–8.76 ng/mL (≈0.003–0.028 µM) | Single 25 mg oral dose, human; range spans low-fat/isolate (lowest) to high-fat/isolate (highest) meal and delivery conditions[6] |
Clinical Dose Context
| Context | Dose | Source |
|---|---|---|
| Acute anxiolytic trial (Cuttler 2024) | 20 mg, single oral dose | RCT — behavioural endpoint only[5] |
| Food-effect / delivery-system trial (Story 2024) | 25 mg, single oral dose | PK study, meal and formulation compared[6] |
| Single-ascending-dose safety study (Wolinsky 2026) | 25–200 mg, single oral doses | Safety and PK/PD, no repeated dosing[7] |
Every controlled human study of CBG published to date has used a single, acute dose — no repeated-dosing or steady-state human pharmacokinetic data exist for CBG at any endpoint.
Formulation Effects
Formulation may matter more for CBG than the human literature alone would suggest, and the available comparisons don't point in one consistent direction. In rats, a nanoemulsion formulation of CBG produced an 8-fold increase in bioavailability via lymphatic transport and a 71-fold increase via the portal vein, compared with a standard oil solution at the same 15 mg oral dose — the largest formulation-driven gap of four cannabinoids tested side by side in that study.[12] In horses, at a higher 10 mg/kg oral dose, an oil formulation and a micellar formulation reached statistically indistinguishable total bioavailability, though the micellar version absorbed faster.[13] In the one human study to test this directly, the result ran counter to the usual assumption that emulsification improves absorption: a plain isolate reached higher peak plasma concentration and total exposure than an MCT-emulsion delivery vehicle at the same 25 mg dose, and this difference only appeared under high-fat meal conditions — under low-fat conditions, isolate and emulsion performed the same.[6]
| Comparison | Species / dose | Result |
|---|---|---|
| Nanoemulsion vs. standard oil | Rat, 15 mg oral | 8-fold to 71-fold higher bioavailability for nanoemulsion[12] |
| Micellar vs. standard oil | Horse, 10 mg/kg oral | No significant bioavailability difference; micellar absorbed faster[13] |
| High-fat vs. low-fat meal | Human, 25 mg oral | Higher peak plasma concentration with high-fat meal[6] |
| Isolate vs. MCT-emulsion | Human, 25 mg oral | Isolate reached higher Cmax and AUC than the emulsion, specifically under high-fat conditions; no difference under low-fat conditions[6] |
Across all three studies, formulation type, species, dose, and absorption pathway all differ, and none of the three agree on a single direction of effect — the rat data favour nanoemulsion dramatically, the horse data show no difference between oil and micellar, and the human data actually favour plain isolate over an MCT-emulsion, under high-fat conditions specifically. This is an unresolved set of differences rather than a single contradiction, and the literature reviewed doesn't isolate which factor (species, formulation chemistry, dose, or meal condition) is driving the divergence. Neither the rat nor horse formulation strategy has been shown to reach tumour tissue in humans; all three studies measure blood levels, not confirmed tumour exposure.[6,12,13]
Metabolism and Pharmacogenomics
CBG undergoes substantial first-pass hepatic metabolism, primarily through a single enzyme (CYP2J2), producing hydroxylated and di-oxygenated metabolites, and is excreted in urine predominantly in glucuronide-conjugated form.[12] Cross-species data from horses is consistent with this pattern in its general shape — extensive phase I hydroxylation and epoxidation, followed by phase II glucuronidation, with the glucuronide metabolite reaching substantially higher plasma exposure than the parent compound — though this is offered as mechanistic corroboration from another species, not a human pharmacokinetic figure.[13]
No pharmacogenomic factor — a genetic variant affecting CYP2J2 activity, for instance — has been reported to change CBG plasma exposure in humans in the sources reviewed. This is an open question, not a settled absence of effect.
Co-Dosing Considerations
This table is deliberately short. No CBG-specific clinical drug-interaction study has been published, and no CBG-specific inhibition, induction, or interaction data exist in humans — interaction risk during cancer treatment is genuinely unknown rather than demonstrated. The guidance below reflects that uncertainty; it is not a documented interaction on record, the way it is for some better-studied cannabinoids. Each row is flagged by the most cautious guidance its cited evidence supports.
Discuss whether to combine, separate, or avoid CBG and a medication with your treating oncology team or physician.
| Flag | Interaction |
|---|---|
| Caution | Drugs cleared primarily through CYP-mediated hepatic metabolism, including many oncology agents. No clinical CBG-drug interaction study has been published. CBG undergoes hepatic metabolism via CYP2J2, but substrate status alone does not establish that it meaningfully inhibits or induces CYP enzymes in humans — no inhibition, induction, or interaction data exist for CBG specifically. Additional caution is reasonable with narrow-therapeutic-index medicines and during systemic cancer treatment because that data gap remains unresolved, not because a specific interaction mechanism has been confirmed.[12] |
| Monitor | Sedatives and alcohol — controlled acute human trials of CBG did not find clinically meaningful sedation or impairment; sleepiness has been reported by some regular users in uncontrolled survey data. Concurrent use with other CNS-depressant substances is reasonable to monitor as a general precaution, not because a demonstrated CBG interaction exists.[5,7,8] |
Advertisement
04 — Onset & Washout
Onset and Washout
CBG's timing profile is honestly thinner than the mechanistic evidence would suggest — every human study to date has used a single dose, so most of what's known about sustained use and clearance comes from animal data or reasonable inference rather than direct human measurement.
Immediate Onset
A single oral dose was reported to measurably reduce anxiety and stress, with no impairment. How long that effect persists afterward hasn't been measured.
Steady State
No repeated-dosing human study has been published, so how CBG behaves with daily use — and whether it builds up in the blood — is genuinely unknown, not just under-reported.
Accumulated Effect
No repeated-dosing human data exist, so whether CBG's preclinical pathway effects — cell-cycle arrest, apoptosis, growth-receptor blockade — need sustained exposure to matter in a person hasn't been tested directly.
Dosing Pattern in Studies
With no repeated-dosing or washout data in humans, the evidence doesn't yet support calling CBG a continuity compound or a pulse-dosed one — that distinction awaits future research.
Washout
How long CBG's influence can take to clear before it stops being a relevant factor — genuinely unclear for this compound.
A human study has measured CBG's terminal half-life after a single 25 mg oral dose: roughly 3–5 hours, varying by meal fat content and delivery vehicle. That's a real number, but it isn't a washout window — no repeated-dose clearance or steady-state data exist for CBG. A cross-species clue on the caution side: in horses, CBG's terminal half-life ran 29 to 46 hours, considerably longer than the human single-dose figure, though it hasn't been confirmed whether that reflects a real species difference or a dosing/route difference.
Two Distinct Clocks
CBG's evidence points toward two mechanistically distinct kinds of effect, on two different timelines — but unlike a compound with a fuller human dataset, only one of those two clocks has actually been measured directly in a person. The other is inferred from preclinical mechanism, not yet confirmed against real timing data.
The direct-pharmacology clock (Clock A) is the one with real human data behind it: a single oral dose measurably reduced anxiety and stress relative to placebo, with no impairment.[5] How long that effect lasts afterward — whether it fades in hours or persists longer — hasn't been measured in any published study. Separately, a pharmacokinetic study found CBG plasma concentration itself peaks relatively quickly after an oral dose — between roughly 45 minutes and just under 2 hours, depending on meal fat content and delivery vehicle — though plasma peak timing and the timing of any subjective effect are not necessarily identical, and the two haven't been measured together in the same study.[6]
| Clock A — Direct Pharmacology | Clock B — Downstream Pathway Effects | |
|---|---|---|
| Latency | Fast — detectable after a single dose | Not established |
| Persistence | Not established beyond the period measured | Not established |
| What it covers | Acute subjective effects — anxiety and stress reduction | Apoptosis, growth-receptor blockade, immune-visibility restoration — documented preclinically only |
The downstream-pathway clock (Clock B) is where the mechanistic case for CBG's oncology relevance actually lives — the apoptosis, growth-receptor blockade, and immune-restoration mechanisms detailed throughout Evidence Summary and Pathway Interaction Profile above. All of that evidence comes from cell and animal studies using sustained or repeated exposure; none of it has been tested against a defined human dosing schedule, so no latency or persistence figure for Clock B has been established. A single human dose, the only kind tested so far, realistically only touches Clock A.
Steady State and Accumulation
No repeated-dosing human study of CBG has been published, so whether — or how quickly — plasma levels reach steady state with daily use, and whether they accumulate above single-dose levels, is genuinely unknown rather than simply under-reported. Cross-species animal data offer an indirect clue rather than an answer: a horse pharmacokinetic study reported a terminal half-life of 29 to 46 hours depending on formulation and route, alongside a metabolite that reached substantially higher plasma exposure than the parent compound.[13] Whether a similar pattern holds in humans has not been tested.
Dosing Pattern in Studies
The gap running through this entire profile is sharper for CBG than it is for most compounds on this site: the mechanistic case is genuinely wide, spanning direct cell killing, growth-receptor blockade, and immune restoration (see Pathway Interaction Profile above) — but almost none of it has been tested against any defined human dosing schedule, let alone the achievable-concentration question detailed under Pharmacokinetics and Administration above. That combination — a wide mechanistic case paired with essentially no human timing or exposure data — is what keeps CBG's real-world confidence low regardless of how promising the preclinical picture looks.
CBG cannot yet be classified as a continuity compound or a pulse-credible one, because that classification depends on data — repeated-dosing and washout studies — that don't yet exist for CBG in humans. The only human effect confirmed so far is Clock A's acute, single-dose behavioural signal; whether Clock B's preclinical pathway effects would require days, weeks, or an achievable dose at all to matter in a person is an open question, not a settled one.
Washout
A controlled human study has measured CBG's terminal half-life after a single 25 mg oral dose, so this isn't a complete blank the way some other CBG parameters are: terminal half-life ranged from roughly 2.9 to 4.9 hours across the four meal/delivery-vehicle combinations tested (low-fat/emulsion, low-fat/isolate, high-fat/emulsion, high-fat/isolate), with no statistically significant difference between delivery vehicles within either meal condition.[6] What's genuinely absent is a clinically validated washout window — repeated-dose terminal kinetics, steady-state accumulation, and elimination after chronic use have not been characterised in humans, and a single-dose half-life figure doesn't substitute for any of those. A cross-species data point offers an additional, indirect clue: a horse pharmacokinetic study reported a terminal half-life of 29 to 46 hours — considerably longer than the human single-dose figure above — alongside extensive metabolite formation.[13] Whether that reflects a genuine species difference, a dose difference (the horse study used a substantially higher dose), or a route/formulation difference is not established in the literature reviewed; it is not a substitute for the missing human repeated-dose and washout data either way.
Until human washout data exist, the only responsible guidance is to raise any planned change in medication, surgery, or procedure with a care team as early as possible, rather than relying on an assumed clearance window that hasn't been established for this compound.
Advertisement
05 — Safety
Safety Profile
CBG has been well tolerated in every human study published so far, but those studies are small, acute, and few — the safety picture for CBG is thinner than for a compound with a longer clinical track record, and that thinness is itself worth stating plainly.
Dry mouth, sleepiness, and dry eyes — the most commonly self-reported effects among regular users in survey data; not confirmed in a controlled trial setting.
No safety data above 200 mg — the highest dose tested in a controlled human study was 200 mg, with no robust pharmacodynamic effects observed up to that point. Exposure above it is untested, so caution is warranted at higher doses.
Withdrawal-type symptoms in regular users — reported in self-report survey data among regular users on stopping use; not confirmed in a controlled trial.
Drug-interaction potential not characterised — no CBG-specific clinical interaction study has been published, and no data exist on whether CBG meaningfully inhibits or induces drug-metabolizing enzymes in humans. Interaction risk during cancer treatment is unknown rather than demonstrated.
Adverse Effects in Human Trials
The safety signal from human trials is reassuring but thin: no serious adverse event has been reported in any published CBG trial, across doses from 20 mg up to 200 mg.[5,7] What was reported instead were mild effects, mostly from self-report survey data rather than controlled-trial adverse-event logging.
In a single-ascending-dose safety study climbing from 25 mg up to 200 mg, CBG produced no robust pharmacodynamic effects and was described as well tolerated throughout — a reassuring finding, though the study's authors themselves noted that chronic-dosing data are still needed to fully characterise CBG's safety profile.[7] In the acute anxiolytic trial, a 20 mg dose produced no significant motor or cognitive impairment.[5] A separate pharmacokinetic study (25 mg, n=19) reported no adverse effects for any meal condition or delivery vehicle tested.[6] In a self-report survey of regular CBG-predominant cannabis users — not a controlled trial, and worth reading with that caveat — dry mouth, sleepiness, and dry eyes were the most commonly reported effects, and some regular users reported withdrawal-type symptoms on stopping.[8]
Hepatic Safety
One human safety study specifically examined liver enzyme response under acute CBG dosing, motivated by documented hepatic concerns with high-dose CBD — but the specific quantitative liver-enzyme findings from that study were not available in the sources reviewed. The study's own overall conclusion was that CBG was well tolerated across the dose range tested.[7]
No FDA or EMA safety warning specific to isolated CBG has been identified in the sources reviewed, and no case of CBG-attributed drug-induced liver injury was found. There is insufficient evidence to define whether liver-function monitoring is necessary for isolated CBG specifically — no CBG hepatotoxicity signal has been documented, and no repeated-dose exposure or recognised risk threshold exists to base a specific recommendation on. Patients with hepatic impairment, or those receiving other hepatotoxic medicines, should discuss CBG use with their treating clinician.
06 — Sourcing
Sourcing Guide
Formulation is the biggest factor in whether a CBG product can deliver anything close to what the research above describes — this compound's own formulation data show an unusually large, if unresolved, gap between delivery methods. Brand quality, ease of access and compound concentrations matter too. Our Sourcing Guide offers a curated list of products available on the retail market we found to answer all of those concerns.
CBG Sourcing Guide07 — Literature
References
Last reviewed: July 2026